Saturday 17 October 2026
Export JSPR’s income statement to Excel — free account
Jasper Therapeutics, Inc.
JSPR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.3% and free cash flow grew 55.7%, each against the same quarter a year earlier.
0.48
0.05
−9.43%
Follow JSPR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (255.05%) | (244.21%) | (230.31%) | (191.12%) |
+8 more TTM periods Free account |
|
| (109.05%) | (141.49%) | (131.06%) | (116.04%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(839.17%) | (489.88%) | (351.79%) | (262.88%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.10) | (2.40) | (4.03) | (4.60) | |
Free Cash Flow |
(60.25) | (68.87) | (77.16) | (76.50) | |
Capital Expenditures |
0.08 | — | 0.01 | (0.07) | |
| Other line items | |||||
Cash ROIC |
(658.92%) | (392.54%) | (234.92%) | (122.46%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.90 | 1.24 | 1.02 | 0.84 | |
Depreciation/Fixed assets |
9.35 | 9.85 | 10.35 | 0.92 | |
Capex/Depreciation |
0.14 | 0.00 | 0.00 | (0.07) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.10) | (2.40) | (4.03) | (4.59) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates